fbpx Skip to main content

Some individuals with asthma experience frequent exacerbations associated with eosinophilic inflammation. Often, these patients are taking multiple asthma medications, including inhaled glucocorticoids and oral glucocorticoids. The purpose of this study was to examine the results of administering mepolizumab to members of this cohort.

The group used for this study, published in the New England Journal of Medicine, consisted of patients who experienced asthma exacerbations with eosinophilic inflammation despite taking high doses of inhaled glucocorticoids. The 576 patients were divided into three groups: a placebo group, a group receiving an intravenous dose of mepolizumab, and a group receiving a subcutaneous dose of mepolizumab. Each group received their dose once every four weeks for 32 weeks.

An assessment of asthma symptoms and severity was performed by measuring the rate of exacerbations, forced expiratory volume in one second, scores on the St. George Asthma Questionnaire, and scores on the 5-item Asthma Control Questionnaire.

Researchers found significant improvement in symptoms for patients receiving varying forms of mepolizumab. Specifically, the rate of exacerbations was reduced by 47% in participants receiving intravenous mepolizumab and by 53% in those receiving subcutaneous mepolizumab compared to placebo recipients.

For patients receiving intravenous mepolizumab, exacerbations that required hospitalization were decreased by 32% compared to 61% in those receiving the subcutaneous dose. Participants receiving both forms of mepolizumab also exhibited improvement according to their questionnaire scores and forced expiratory volume test results.

The researchers concluded that based on this trial, mepolizumab exhibits promising results in significantly reducing exacerbations that are otherwise difficult to control [1].


You May Also Like::  Targeting Metabolic Pathways for Asthma Treatment in Patients With Obesity
[1] Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., & Chanez, P. (2014). Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine, 371(13), 1198–1207. https://doi.org/10.1056/nejmoa1403290

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More